TLR4-induced IFN-γ production increases TLR2 sensitivity and drives Gram-negative sepsis in mice

Gram-negative bacterial infection is a major cause of sepsis and septic shock. An important inducer of inflammation underlying both syndromes is the cellular recognition of bacterial products through pattern recognition receptors (PRRs), including Toll-like receptors (TLRs). We identified a novel antagonistic mAb (named 1A6) that recognizes the extracellular portion of the TLR4–MD-2 complex. If applied to mice before infection with clinical isolates of Salmonella enterica or Escherichia coli and subsequent antibiotic therapy, 1A6 prevented otherwise fatal shock, whereas application of 1A6 after infection was ineffective. In contrast, coapplication of 1A6 and an anti-TLR2 mAb up to 4 h after infection with Gram-negative bacteria, in combination with the start of antibiotic therapy (mimicking clinical conditions), provided robust protection. Consistent with our findings in mice, dual blockade of TLR2 and TLR4 inhibited TNF-α release from human peripheral blood mononuclear cells upon Gram-negative bacterial infection/antibiotic therapy. Both murine splenocytes and human PBMCs released IFN-γ in a TLR4-dependent manner, leading to enhanced surface TLR2 expression and sensitivity for TLR2 ligands. Our results implicate TLR2 as an important, TLR4-driven sensor of Gram-negative bacterial infection and provide a rationale for blockade of both TLRs, in addition to antibiotic therapy for the treatment of Gram-negative bacterial infection.

[1]  Samuel I. Miller,et al.  Salmonellae interplay with host cells , 2008, Nature Reviews Microbiology.

[2]  R. Ulevitch,et al.  TLR4/MD-2 Monoclonal Antibody Therapy Affords Protection in Experimental Models of Septic Shock , 2007, The Journal of Immunology.

[3]  B. Monks,et al.  Ligand-induced conformational changes allosterically activate Toll-like receptor 9 , 2007, Nature Immunology.

[4]  T. Hartung,et al.  Cellular Recognition of Trimyristoylated Peptide or Enterobacterial Lipopolysaccharide via Both TLR2 and TLR4* , 2007, Journal of Biological Chemistry.

[5]  R. Modlin,et al.  Therapeutic implications of the TLR and VDR partnership. , 2007, Trends in molecular medicine.

[6]  J. Pugin,et al.  Contribution of Toll-like receptors to the innate immune response to Gram-negative and Gram-positive bacteria. , 2007, Blood.

[7]  R. Hotchkiss,et al.  Apoptosis and caspases regulate death and inflammation in sepsis , 2006, Nature Reviews Immunology.

[8]  T. van der Poll,et al.  Toll-like receptor mRNA levels in alveolar macrophages after inhalation of endotoxin , 2006, European Respiratory Journal.

[9]  Y. Vodovotz,et al.  Hemorrhagic shock-activated neutrophils augment TLR4 signaling-induced TLR2 upregulation in alveolar macrophages: role in hemorrhage-primed lung inflammation. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[10]  R. Munford Severe sepsis and septic shock: the role of gram-negative bacteremia. , 2006, Annual review of pathology.

[11]  L. McIntyre,et al.  Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity , 2005, Canadian Medical Association Journal.

[12]  S. Calvano,et al.  Expression of tumour necrosis factor receptor and Toll‐like receptor 2 and 4 on peripheral blood leucocytes of human volunteers after endotoxin challenge: a comparison of flow cytometric light scatter and immunofluorescence gating , 2005, Clinical and experimental immunology.

[13]  D. May,et al.  Proposed mechanisms and preventative options of Jarisch–Herxheimer reactions , 2005, Journal of clinical pharmacy and therapeutics.

[14]  D. Persing,et al.  A Synthetic TLR4 Antagonist Has Anti-Inflammatory Effects in Two Murine Models of Inflammatory Bowel Disease 1 , 2005, The Journal of Immunology.

[15]  Kevin J. Tracey,et al.  High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal , 2005, Nature Reviews Immunology.

[16]  Shizuo Akira,et al.  Toll-like receptor signalling , 2004, Nature Reviews Immunology.

[17]  Stefan Bauer,et al.  Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. , 2004, The Journal of clinical investigation.

[18]  H. Wagner,et al.  Differential Contribution of Toll-Like Receptors 4 and 2 to the Cytokine Response to Salmonella enterica Serovar Typhimurium and Staphylococcus aureus in Mice , 2003, Infection and Immunity.

[19]  S. Akira,et al.  Role of Adaptor TRIF in the MyD88-Independent Toll-Like Receptor Signaling Pathway , 2003, Science.

[20]  Jonathan Cohen The immunopathogenesis of sepsis , 2002, Nature.

[21]  Carl Nathan,et al.  Points of control in inflammation , 2002, Nature.

[22]  F. Sennhauser,et al.  Expression of CD14 and Toll-like receptor 2 in farmers' and nonfarmers' children , 2002, The Lancet.

[23]  R. Bucala,et al.  Protection from septic shock by neutralization of macrophage migration inhibitory factor , 2000, Nature Medicine.

[24]  R. Ulevitch,et al.  Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. Schumann,et al.  LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. , 1998, The Journal of clinical investigation.

[26]  R. Ulevitch,et al.  Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. , 1995, Annual review of immunology.

[27]  B. Ryffel,et al.  Interferon gamma receptor deficient mice are resistant to endotoxic shock , 1994, The Journal of experimental medicine.

[28]  R. Zinkernagel,et al.  Immune response in mice that lack the interferon-gamma receptor. , 1993, Science.